Highlights

• Mesoblast was featured at the Australian Securities Exchange Investor Day in Melbourne, presented as a commercial-stage biotechnology company following the FDA approval of Ryoncil.

• Ryoncil (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell therapy, indicated for steroid-refractory acute graft-versus-host disease in paediatric patients.

• The company outlined priorities including expanding Ryoncil into adult acute graft-versus-host disease and advancing rexlemestrocel-L for inflammatory chronic low back pain and heart failure.

• Mesoblast holds a portfolio of over 1,000 granted patents or Patent applications providing commercial protection extending to at least 2044 in major markets.

Mesoblast Limited (ASX:MSB), a global developer of allogeneic cellular medicines for inflammatory diseases, was featured at the Australian Securities Exchange Investor Day in Melbourne, where the company presented its transformation into a commercial-stage biotechnology enterprise. The presentation covered the ongoing commercialisation of its FDA-approved product Ryoncil, the company's plans for expanding that product into additional indications and its development pipeline targeting several other high-value disease areas.

Ryoncil Commercialisation and Expansion

Ryoncil (remestemcel-L-rknd) is Mesoblast's first approved commercial product and represents a landmark in cellular medicine — it is the first FDA-approved mesenchymal stromal cell therapy globally, cleared for the treatment of steroid-refractory acute graft-versus-host disease in paediatric patients aged two months and older. The FDA approval positions Mesoblast in a relatively early but commercially meaningful segment of the broader cellular therapy market.

A key near-term expansion opportunity involves bringing Ryoncil into adult patients with the same indication — steroid-refractory acute graft-versus-host disease. This would substantially broaden the addressable patient population for the product. Additionally, the company has described plans to develop Ryoncil for biologic-resistant inflammatory bowel disease, another severe inflammatory condition for which treatment Options remain limited.

Pipeline Development: Heart Failure, Back Pain and Beyond

Beyond Ryoncil, Mesoblast's development pipeline centres on rexlemestrocel-L, its second cellular therapy platform. This product candidate is being developed across multiple indications, with the two most advanced being inflammatory chronic low back pain and cardiopulmonary applications covering end-stage heart failure and pulmonary hypertension related to left ventricular function.

Chronic low back pain is one of the most prevalent and costly musculoskeletal conditions globally. The inflammatory component that underpins many cases of chronic low back pain may respond to the anti-inflammatory mechanism of action that characterises Mesoblast's mesenchymal lineage cell therapies, which work by releasing factors that modulate the immune system's inflammatory processes. The company has conducted Clinical Trials in this area and continues to advance the programme.

In cardiopulmonary disease, the company's focus on end-stage heart failure represents a severe and underserved patient population with limited therapeutic options. The clinical rationale is consistent with Mesoblast's platform mechanism — damping excess inflammation that contributes to cardiac dysfunction.

Platform, Manufacturing and Intellectual Property

Mesoblast's technology platform is built on its mesenchymal lineage cell therapy approach, which involves using off-the-shelf, cryopreserved cellular medicines manufactured at industrial scale from donor cells. The allogeneic, or off-the-shelf, nature of the product is considered commercially important: it means that treatment does not need to be customised for each patient, as would be the case with autologous cell therapies, potentially enabling wider and more practical clinical deployment.

The company has described its manufacturing as producing industrial-scale, cryopreserved cellular medicines with defined pharmaceutical release criteria. These are designed to be available to patients without the delays inherent in custom manufacturing. Supporting this platform is a broad intellectual property portfolio of over 1,000 granted patents or patent applications, covering compositions of matter, manufacturing methods and specific disease indications, with protection extending to at least 2044 in major markets.

Key Takeaways

• Mesoblast was featured at the ASX Investor Day following its transformation into a commercial-stage company anchored by the FDA approval of Ryoncil.

• Key near-term development priorities include expanding Ryoncil into adult graft-versus-host disease patients and advancing rexlemestrocel-L in heart failure and chronic low back pain.

• The company's allogeneic cell therapy platform enables off-the-shelf treatment at industrial scale, a differentiating feature relative to patient-specific cell therapies.

• Mesoblast holds a substantial intellectual property portfolio protecting its platform and products in major global markets through to at least 2044.